Novo Nordisk: Downgrading To 'Sell' As GLP-1 Pipeline Faces Many Risks [Seeking Alpha]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Seeking Alpha
CagriSema failed to achieve non-inferior weight loss versus Eli Lilly's tirzepatide in the pivotal REDEFINE-4 study, undermining NVO's obesity drug pipeline momentum. Oral Wegovy approval is offset by the launch of Eli Lilly's Foundayo, which offers competitive advantages and limits NVO's market edge. NVO faces a -5% to -13% sales growth outlook for 2026, pressured by generic semaglutide entry in some markets and a thin late-stage pipeline. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » sankai/iStock via Getty Images The last time I wrote on Novo Nordisk NVO ), it was with a Seeking Alpha article entitled " Novo Nordisk: CagriSema Sets Potential Obesity Drug Development Comeback ." With respect to this article, I More on my IG service This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketp
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Aspect Biosystems receives funding for cellular medicine project [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk CEO says weight-loss drug boom has barely begun [Seeking Alpha]Seeking Alpha
- Eli Lilly's One-Two Punch Could Knock Novo Nordisk Out of the Obesity Drug Fight [Yahoo! Finance]Yahoo! Finance
- Asian travelers seek respite in other options as Middle East travel plans stay grounded Share Share VIDEO 9:54 09:54 How will Middle East flight disruptions and FX moves affect tourism in Asia? [CNBC]CNBC
- Why Novo Nordisk's Pricing Shift Could Unlock a Much Larger Obesity Market [Yahoo! Finance]Yahoo! Finance
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 3/30/26 - Form 6-K
- 3/27/26 - Form 6-K
- 3/27/26 - Form 6-K
- NVO's page on the SEC website